Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises Neusoft Xikang on Hong Kong IPO and Listing

  • en
  • zh
  • Language options

28 September 2023

Clifford Chance advises Neusoft Xikang on Hong Kong IPO and Listing

Global law firm Clifford Chance has acted as the international counsel to Neusoft Xikang Holding Inc. ("Neusoft Xikang") for its initial public offering and listing on the mainboard of the Hong Kong Stock Exchange.

The deal was led by China Co-Managing Partner Tim Wang and partners Fang Liu and Christine Xu with support from counsel Claire Cao, senior associates Emma Bao and Qingqing Bu, associates Yuan Cao, Yuer Shao, Xiao Yu and Jason Ng and trainee Xiao Tang.

Tim said, "We're honoured to assist Neusoft Xikang on its successful listing, which demonstrates our expertise advising the healthcare sector on IPOs and extensive experience in the Hong Kong equity capital market."

As one of the pioneers in China's digital healthcare market, Neusoft Xikang developed China's first city-specific hospital network and nurtured a hospital network on a cloud-based system that connects local governments, medical institutions, patients and insurers to enable equal access to medical resources and a more effective and efficient delivery of health care services.

Clifford Chance regularly advises on many of Hong Kong’s most significant healthcare IPOs, including Adicon, Sipai Health Technology, Dingdang Pharma, Medlive Technology and Ping An Doctor.

高伟绅助力东软熙康首次公开发行及香港联交所上市

国际领先律师事务所高伟绅就东软熙康控股有限公司(“东软熙康”)约8200万美元首次公开发行及香港联交所主板上市,担任其国际法律顾问。

中国区联席管理合伙人王彦峰、合伙人方刘和许文嘉共同牵头本交易,团队成员包括曹阳 (外国法律顾问律师)、包宸、卜青青、曹嫄、邵钰儿、俞笑、吴子轩和唐潇。

王彦峰律师表示:我们很荣幸能协助东软熙康成功上市,此项目再次彰显了高伟绅在医疗健康领域的专业知识以及香港股权资本市场的丰厚经验。

东软熙康作为中国数字医疗服务市场的先行者之一,是中国首个以城市为入口的云医院平台,并建立了一个云医院网络,将地方政府、医疗机构、患者、保险公司联系起来,以实现公平地获得医疗资源并更有效和高效地交付医疗服务。

高伟绅近年来参与了众多医疗行业香港上市项目,包括艾迪康、思派健康科技、叮当健康、医脉通和平安好医生等。